No CrossRef data available.
Article contents
Polymyxin B Consumption and Incidence of Gram-Negative Bacteria Intrinsically Resistant to Polymyxins
Published online by Cambridge University Press: 02 January 2015
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

- Type
- Letters to the Editor
- Information
- Copyright
- Copyright © The Society for Healthcare Epidemiology of America 2012
References
1.Zavascki, AP, Goldani, LZ, Li, J, Nation, RL. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 2007;60:1206–1215.CrossRefGoogle ScholarPubMed
2.Nation, RL, Li, J. Colistin in the 21st century. Curr Opin Infect Dis 2009;22:535–543.Google Scholar
3.Streit, JM, Jones, RN, Sader, HS, Fritsche, TR. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int J Antimicrob Agents 2004;24:111–118.Google Scholar
4.Kontopidou, F, Plachouras, D, Papadomichelakis, E, et al. Colonization and infection by colistin-resistant gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect 2011; 17: E9–E11.Google Scholar
5.World Health Organization. Guidelines for DDD Classification and DDD Assignment 2010. Oslo: World Health Organization, 2009.Google Scholar